Skip to main content

PDC*line Pharma and partners receive €8.1M from Walloon region and Wallonia health cluster BioWin for personalized therapeutic vaccine project

PDC*line Pharma and partners receive €8.1M from Walloon region and Wallonia health cluster BioWin for personalized therapeutic vaccine project PDC*neo+ project aims to develop personalized therapeutic vaccine based on neoantigens for colorectal cancer Collaborative effort between biotechnology companies, PDC*line Pharma and OncoDNA, technology company salamanderU and universities UCLouvain–IREC/MIRO and ULB-BCTL…

Read More

Bioxodes closes €12 million in Series A funding round

Bioxodes closes €12 million in  Series A funding round Funding will enable Bioxodes to continue clinical development of drug candidate for patients with intracerebral hemorrhage Recruitment of first patient for phase IIa proof-of-concept clinical trial due before end of Q4, 2023 Gosselies, Belgium, November 21, 2023 – Bioxodes SA, a biopharmaceutical company specializing…

Read More

AbolerIS Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases

AbolerIS Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases Financing round led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital. AbolerIS is developing a first-in-class drug inducing an immune tolerance-based mechanism that acts…

Read More

Belgian biotech companies DeuterOncology and Radiomics combine their expertise to improve cancer therapy

Belgian biotech companies DeuterOncology and Radiomics combine their expertise to improve cancer therapy DeuterOncology obtains SPW grant funding Liège, Belgium, April 07, 2023 – DeuterOncology, a Liège-Based (BE) biotech company, is pleased to announce it has successfully been awarded the Win4Company grant by the Wallonie recherche SPW. The clinical-stage drug...
Read More

ImmuneWatch, Quantoom Biosciences (Univercells) and UAntwerp join forces to explore new in vitro and in silico assays that predict T cell responses in vaccines

March 30, 2023 Quantoom Biosciences (“Quantoom”), ImmuneWatch and UAntwerp (Lab of Experimental Hematology) are delighted to announce a public-private partnership in a project under the “Pandemic Preparedness” call, launched by the University of Antwerp in 2022. “The goal of this project is to assess if a detailed analysis of the...
Read More